What Factors Propelled The Growth Of The Oligonucleotide Therapy Market In The Past?
The oligonucleotide therapy market has seen considerable growth due to a variety of factors.
• The market size for oligonucleotide therapy has enjoyed swift expansion in the recent past. It is projected to rise from $5.55 billion in 2024 to $6.18 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 11.4%.
Factors contributing to this growth during the historical period include increased investment in research and development, the introduction of early treatments, the emergence of gene editing methods, advancements in therapeutic discoveries, and the introduction of rnai and antisense oligonucleotide.
What Does Future Hold for The Oligonucleotide Therapy Market Size?
The oligonucleotide therapy market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of oligonucleotide therapy is predicted to experience a fast-paced growth in the upcoming years, reaching $9.82 billion by 2029 with a compound annual growth rate (CAGR) of 12.3%.
This growth in the projection period can be credited to investments in research and development, penetration of the global market, expansion in the therapeutic area, strategies for disease modification, and regulatory adjustments. Prominent trends for the forecasted period include personalized therapies, advancements in delivery systems, improvements in RNA interference (RNAI), innovation in antisense oligonucleotide, and the incorporation of gene editing techniques.
What Main Forces Are Fueling Expansion In The Oligonucleotide Therapy Market?
The global increase in cancer cases is expected to drive the growth of the oligonucleotide therapy market in the forecast period. According to the American Cancer Society in January 2022, an estimated 1.9 million new cancer diagnoses and 609,360 cancer-related deaths are projected for the US, with approximately 1,670 deaths occurring daily. The most prevalent types of cancer worldwide include lung, prostate, bowel, and female breast cancer, which constitute 43 percent of all new cancer diagnoses. Thus with the worldwide surge in cancer incidence rates, a heightened demand for the oligonucleotide therapy market is projected in the upcoming years.
What Is The Segmentation Of The Global Oligonucleotide Therapy Market?
The oligonucleotide therapy market covered in this report is segmented –
1) By Type: Antisense Oligonucleotide, Aptamer, Other Types
2) By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User
3) By End User: Hospitals, Research Institutes
Subsegments:
1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides
2) By Aptamer: DNA Aptamers, RNA Aptamers, Small Molecule Aptamers
3) By Other Types: siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing
Pre-Book The Oligonucleotide Therapy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Oligonucleotide Therapy Market?
Participants in the oligonucleotide therapy market, both creators and suppliers, are pouring resources into research and development, aiming to refine the therapy structure to minimize any adverse effects on patients. The advanced oligonucleotides facilitate precision medicine strategies and can be fine-tuned to selectively target any gene while keeping side effects to a minimum. Moreover, it enables targeting sequences specific to each patient which are responsible for causing rare diseases. The FDA gave its approval to Qalsody, an antisense oligonucleotide (ASO), for the treatment of patients with a form of amyotrophic lateral sclerosis (ALS) linked to a mutation in the superoxide dismutase 1 (SOD1) gene in April 2023. Qalsody works by targeting SOD1 mRNA, thereby, curtailing the production of SOD1 protein.
Who Are the Key Players in the Oligonucleotide Therapy Market?
Major companies operating in the oligonucleotide therapy market include:
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• Gilead Sciences Inc.
• BioNTech SE
• Moderna Inc.
• Biogen Inc.
• Jazz Pharmaceuticals plc
• QIAGEN Company
• Alnylam Pharmaceuticals Inc.
• Sarepta Therapeutics Inc.
• Ionis Pharmaceuticals Inc.
• Akcea Therapeutics Inc.
• Arrowhead Pharmaceuticals Inc.
• Dicerna Pharmaceuticals Inc.
• SomaGenics Inc.
• Wave Life Sciences Ltd.
• Exicure Inc.
• Avidity Biosciences Inc.
• Miragen Therapeutics Inc.
• ProQR Therapeutics NV
• Regulus Therapeutics Inc.
• Kastle Therapeutics LLC
• Santaris Pharma A/S
• InteRNA Technologies B.V.
• Dynacure S.A.
• Arcturus Therapeutics Holdings Inc.
• Intellia Therapeutics Inc.
• Regeneron Pharmaceuticals Inc.
• Editas Medicine Inc.
• Evox Therapeutics Ltd.
• PepGen Ltd.
What are the Regional Insights into the Oligonucleotide Therapy Market?
North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
